Skip to main content
Erschienen in: Cancer Causes & Control 2/2010

01.02.2010 | Original paper

Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand

verfasst von: Patricia Priest, Lynn Sadler, Peter Sykes, Roger Marshall, Julia Peters, Sue Crengle

Erschienen in: Cancer Causes & Control | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study is to assess whether ethnic inequalities in cervical cancer mortality are due to differences in survival independent of stage and age at diagnosis, and to assess the contribution of screening to stage at diagnosis.

Methods

Demographic data and cervical screening history were collected for 402 women with histologically proven primary invasive cervical cancer, diagnosed in New Zealand between 1 January 2000 and 30 September 2002. Date of death was available for women who died up to 30 September 2004.

Results

A Cox proportional hazard model showed that, after adjusting for age, the Māori mortality rate was 1.80 times (95% CI 1.07–3.04) that of non-Māori. This reduced to 1.25 (95% CI 0.74–2.11) when stage at diagnosis was also adjusted for. Among determinants of late stage at diagnosis, older age and being Māori significantly increased the risk, while screening was protective.

Conclusions

These results indicate that later stage at diagnosis is the main determinant of Māori women’s higher mortality from cervical cancer. Improving cervical screening among Māori women would reduce stage at diagnosis and therefore ethnic inequalities in mortality.
Literatur
1.
Zurück zum Zitat New Zealand Health Information Service (2006) Cancer: new registrations and deaths 2002. Ministry of Health, Wellington New Zealand Health Information Service (2006) Cancer: new registrations and deaths 2002. Ministry of Health, Wellington
3.
Zurück zum Zitat New Zealand Health Information Service (2007) Cancer: new registrations and deaths 2003. Ministry of Health, Wellington New Zealand Health Information Service (2007) Cancer: new registrations and deaths 2003. Ministry of Health, Wellington
4.
Zurück zum Zitat New Zealand Health Information Service (2007) Cancer: new registrations and deaths 2004. Ministry of Health, Wellington New Zealand Health Information Service (2007) Cancer: new registrations and deaths 2004. Ministry of Health, Wellington
5.
Zurück zum Zitat Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX et al (2003) Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study. Cancer Causes Control 14(9):805–814CrossRefPubMed Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX et al (2003) Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study. Cancer Causes Control 14(9):805–814CrossRefPubMed
6.
Zurück zum Zitat Waggoner S, Darcy K, Fuhrman B, Parham G, Lucci Jr J, Monk B (2006) Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol 103:853–858CrossRefPubMed Waggoner S, Darcy K, Fuhrman B, Parham G, Lucci Jr J, Monk B (2006) Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol 103:853–858CrossRefPubMed
7.
Zurück zum Zitat Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP et al (2003) Carcinoma of the cervix uteri. Int J Gynaecol Obstet 83(S1):41–78CrossRefPubMed Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP et al (2003) Carcinoma of the cervix uteri. Int J Gynaecol Obstet 83(S1):41–78CrossRefPubMed
8.
Zurück zum Zitat Westbrooke I, Baxter J, Hogan J (2001) Are Māori under-served for cardiac interventions? N Z Med J 114:484–487PubMed Westbrooke I, Baxter J, Hogan J (2001) Are Māori under-served for cardiac interventions? N Z Med J 114:484–487PubMed
9.
Zurück zum Zitat Independent Monitoring Group (2003) Quarterly Report 10. National Cervical Screening Programme. January–March 2003. Hugh Adam Cancer Epidemiology Unit, Department of Preventive and Social Medicine, University of Otago, Dunedin Report No.:50 Independent Monitoring Group (2003) Quarterly Report 10. National Cervical Screening Programme. January–March 2003. Hugh Adam Cancer Epidemiology Unit, Department of Preventive and Social Medicine, University of Otago, Dunedin Report No.:50
10.
Zurück zum Zitat Priest P, Sadler L, Peters J, Crengle S, Bethwaite P, Medley G et al (2006) Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading. Br J Obstet Gynaecol 114:398–407 Priest P, Sadler L, Peters J, Crengle S, Bethwaite P, Medley G et al (2006) Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading. Br J Obstet Gynaecol 114:398–407
11.
Zurück zum Zitat Sadler L, Priest P, Peters J, Crengle S, Jackson R (2004) The New Zealand Cervical Cancer Audit, Whakamaatau Mate Pukupuku Taiawa o Aotearoa. Ministry of Health, Wellington Sadler L, Priest P, Peters J, Crengle S, Jackson R (2004) The New Zealand Cervical Cancer Audit, Whakamaatau Mate Pukupuku Taiawa o Aotearoa. Ministry of Health, Wellington
13.
Zurück zum Zitat Jeffreys M, Stevanovic V, Tobias M, Lewis C, Ellison-Loschmann L, Pearce N et al (2005) Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public Health 95(5):834–837CrossRefPubMed Jeffreys M, Stevanovic V, Tobias M, Lewis C, Ellison-Loschmann L, Pearce N et al (2005) Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public Health 95(5):834–837CrossRefPubMed
14.
Zurück zum Zitat Robson B, Purdie G, Cormack D (2006) Unequal impact: Māori and Non-Māori cancer statistics 1996–2001. Ministry of Health, Wellington Robson B, Purdie G, Cormack D (2006) Unequal impact: Māori and Non-Māori cancer statistics 1996–2001. Ministry of Health, Wellington
15.
Zurück zum Zitat Te Ropu Rangahau Hauora a Eru Pomare (2000) Counting for nothing: understanding the issues in monitoring disparities in health. Soc Policy J N Z 14:1–16 Te Ropu Rangahau Hauora a Eru Pomare (2000) Counting for nothing: understanding the issues in monitoring disparities in health. Soc Policy J N Z 14:1–16
16.
Zurück zum Zitat Brewer N, Pearce N, Jeffreys M, White P, Ellison-Loschmann L (2009) Demographic differences in stage at diagnosis and cervical cancer in New Zealand, 1994–2005. J Women’s Health 18:955–963CrossRef Brewer N, Pearce N, Jeffreys M, White P, Ellison-Loschmann L (2009) Demographic differences in stage at diagnosis and cervical cancer in New Zealand, 1994–2005. J Women’s Health 18:955–963CrossRef
17.
Zurück zum Zitat Condon J, Barnes T, Armstrong B, Selva-Nayagam S, Elwood M (2005) Stage at diagnosis and cancer survival for Indigenous Australians in the Northern Territory. Med J Aust 182:277–280PubMed Condon J, Barnes T, Armstrong B, Selva-Nayagam S, Elwood M (2005) Stage at diagnosis and cancer survival for Indigenous Australians in the Northern Territory. Med J Aust 182:277–280PubMed
18.
Zurück zum Zitat Newman S, Garner E (2005) Social inequities along the cervical cancer continuum: a structured review. Cancer Causes Control 16:63–70CrossRef Newman S, Garner E (2005) Social inequities along the cervical cancer continuum: a structured review. Cancer Causes Control 16:63–70CrossRef
19.
Zurück zum Zitat Leath C, Straughn MJ, Kirby T, Huggins A, Partridge E, Parham G (2005) Predictors of outcomes for women with cervical cancer. Gynecol Oncol 99:432–436CrossRefPubMed Leath C, Straughn MJ, Kirby T, Huggins A, Partridge E, Parham G (2005) Predictors of outcomes for women with cervical cancer. Gynecol Oncol 99:432–436CrossRefPubMed
20.
Zurück zum Zitat Coker A, Du X, Fang S, Eggleston K (2006) Socioeconomic status and cervical cancer survival among older women: Findings from the SEER-Medicare linked data cohorts. Gynecol Oncol 102:278–284CrossRefPubMed Coker A, Du X, Fang S, Eggleston K (2006) Socioeconomic status and cervical cancer survival among older women: Findings from the SEER-Medicare linked data cohorts. Gynecol Oncol 102:278–284CrossRefPubMed
21.
Zurück zum Zitat Farley J, Hines J, Taylor R, Carlson J, Parker M, Kost E et al (2001) Equal care ensures equal survival for African-American women with cervical cancer. Cancer 91:869–873CrossRefPubMed Farley J, Hines J, Taylor R, Carlson J, Parker M, Kost E et al (2001) Equal care ensures equal survival for African-American women with cervical cancer. Cancer 91:869–873CrossRefPubMed
22.
Zurück zum Zitat Brookfield KF, Cheung MC, Lucci J, Fleming LE, Koniaris LG (2009) Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer 115:166–178CrossRefPubMed Brookfield KF, Cheung MC, Lucci J, Fleming LE, Koniaris LG (2009) Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer 115:166–178CrossRefPubMed
Metadaten
Titel
Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand
verfasst von
Patricia Priest
Lynn Sadler
Peter Sykes
Roger Marshall
Julia Peters
Sue Crengle
Publikationsdatum
01.02.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 2/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-009-9451-7

Weitere Artikel der Ausgabe 2/2010

Cancer Causes & Control 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.